AU2021370222A1 - Method of safe administration of anti-tau antibody - Google Patents

Method of safe administration of anti-tau antibody Download PDF

Info

Publication number
AU2021370222A1
AU2021370222A1 AU2021370222A AU2021370222A AU2021370222A1 AU 2021370222 A1 AU2021370222 A1 AU 2021370222A1 AU 2021370222 A AU2021370222 A AU 2021370222A AU 2021370222 A AU2021370222 A AU 2021370222A AU 2021370222 A1 AU2021370222 A1 AU 2021370222A1
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
tau
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021370222A
Other languages
English (en)
Inventor
David Henley
Lingjue Li
Partha NANDY
Carlos Pérez RUIXO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2021370222A1 publication Critical patent/AU2021370222A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2021370222A 2020-10-26 2021-10-25 Method of safe administration of anti-tau antibody Pending AU2021370222A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105810P 2020-10-26 2020-10-26
US63/105,810 2020-10-26
US202163250114P 2021-09-29 2021-09-29
US63/250,114 2021-09-29
PCT/EP2021/079566 WO2022090169A1 (en) 2020-10-26 2021-10-25 Method of safe administration of anti-tau antibody

Publications (1)

Publication Number Publication Date
AU2021370222A1 true AU2021370222A1 (en) 2023-06-22

Family

ID=78483271

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021370222A Pending AU2021370222A1 (en) 2020-10-26 2021-10-25 Method of safe administration of anti-tau antibody

Country Status (10)

Country Link
US (1) US20220127346A1 (https=)
EP (1) EP4232472A1 (https=)
JP (1) JP2023546503A (https=)
KR (1) KR20230097110A (https=)
AU (1) AU2021370222A1 (https=)
CA (1) CA3199808A1 (https=)
IL (1) IL302383A (https=)
MX (1) MX2023004832A (https=)
TW (1) TW202231661A (https=)
WO (1) WO2022090169A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
US20230235034A1 (en) * 2020-05-26 2023-07-27 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological tau, and methods using same
CA3199806A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity

Also Published As

Publication number Publication date
CA3199808A1 (en) 2022-05-05
KR20230097110A (ko) 2023-06-30
IL302383A (en) 2023-06-01
WO2022090169A1 (en) 2022-05-05
JP2023546503A (ja) 2023-11-02
TW202231661A (zh) 2022-08-16
US20220127346A1 (en) 2022-04-28
EP4232472A1 (en) 2023-08-30
MX2023004832A (es) 2023-07-18

Similar Documents

Publication Publication Date Title
US20230123110A1 (en) High dose treatments for alzheimer's disease
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
US20220062412A1 (en) Treatment of alzheimer's disease (ad) with an aluminum salt
TW202543674A (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
US20220127345A1 (en) Methods of Reducing Tau in Human Subjects
TW202330614A (zh) 抗ｔｒｅｍ２抗體及其用途
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
EP3269376B1 (en) Treatment and prevention of alzheimer's disease (ad)
CN116829582A (zh) 安全施用抗Tau抗体的方法
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку
HK40100358A (zh) 安全施用抗tau抗体的方法
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
HK40100364A (zh) 减少人类受试者中的tau的方法
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
WO2026085535A2 (en) Treatment of pathologies associated with down syndrome with anti-fsh antibodies
EA050381B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов